6/13/2008 Newport, PA press release PharmaLive.com President George W. Bush today appointed world-renowned medical oncologist Waun Ki Hong, M.D., professor and head of the Division of Cancer Medicine at The University of Texas M. D. Anderson Cancer Center, to the National Cancer Advisory Board. Hong will serve a six-year term through March 9, 2014. The function of the NCAB is to advise, assist and make recommendations to the secretary of the Department of Health and Human Services and the director of the National Cancer Institute. The NCAB may make recommendations regarding support grants and cooperative agreements, technical and scientific peer review, and functions pertaining to the NCI. “I am delighted to be selected to serve on the National Cancer Advisory Board by President Bush. This new opportunity will allow me to share my expertise in translational and clinical research, to learn from and collaborate with so many of my distinguished colleagues around the country, and to continue to do my part to shape cancer policy,” said Hong. “My ultimate challenge, both at M. D. Anderson and soon with my work with the NCAB, is very simple: raising the bar in cancer care for all those with this disease.” Since joining M. D. Anderson faculty in 1984, Hong has made seminal contributions to cancer medicine through his pioneering research in larynx preservation and chemoprevention in head and neck cancer. Hong, author or co-author of more than 660 scientific publications, has successfully translated numerous key research findings into effective clinical care during [...]

6/13/2008 web-based article Joel B. Epstein et al. Can Fam Physician Vol. 54, No. 6, June 2008, pp.870 - 8 Objective: To describe the role that primary care physicians can play in early recognition of oral and oropharyngeal squamous cell carcinomas (OOSCCs) and to review the risk factors for OOSCCs, the nature of oral premalignant lesions, and the technique and aids for clinical examination. Quality of Evidence: Medline and Cancerlit literature searches were conducted using the following terms: oral cancer and risk factors, pre-malignant oral lesions, clinical evaluation of abnormal oral lesions, and cancer screening. Additional articles were identified from key references within articles. The articles contained level I, II, and III evidence and included controlled trials and systematic reviews. Main Message: Most OOSCCs are in advanced stages at diagnosis, and treatment does not improve survival rates. Early recognition and diagnosis of OOSCCs might improve patient survival and reduce treatment-related morbidity. Comprehensive head and neck examinations should be part of all medical and dental examinations. The head and neck should be inspected and palpated to evaluate for OOSCCs, particularly in high-risk patients and when symptoms are identified. A neck mass or mouth lesion combined with regional pain might suggest a malignant or premalignant process. Conclusion: Primary care physicians are well suited to providing head and neck examinations, and to screening for the presence of suspicious oral lesions. Referral for biopsy might be indicated, depending on the experience of examining physicians. Authors: Joel B. Epstein, DMD MSD FRCDC FDS Professor in [...]

6/10/2008 Fairfax, VA press release NewsReleaseWire.com Adding radiation therapy to surgery significantly improves overall survival in patients diagnosed with node-positive head and neck cancer when compared to treating with surgery alone, according to a study in the June issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology. Radiation therapy is commonly used after surgery to treat some head and neck cancers, but very few studies have been conducted to determine its impact on survival. Researchers at the Mount Sinai School of Medicine departments of Radiation Oncology and Otolaryngology and Head and Neck Surgery in New York sought to determine with this study the impact of radiation and surgery on a head and neck cancer patients’ overall survival. Between 1988 and 2001, 5,297 patients with a median age of 59 who were diagnosed with node-positive head and neck squamous cell carcinoma were treated with surgery and/or adjuvant radiation therapy. The patients were surveyed approximately 4.4 years after treatment, and the researchers found that adding radiation to surgery improved patients’ chance of survival by 25 percent in all nodal stages (N1-N3), including N1 stage patients, even though radiation is typically recommended only for N2 and N3 stage patients. “This study provides evidence that radiation should be considered after surgery for most head and neck cancer patients with positive lymph nodes,” said Johnny Kao, M.D., assistant professor of radiation oncology at the Mount Sinai School of Medicine and lead author of the [...]

6/9/2008 Houston, TX staff CancerWise (www.cancerwise.org) Whether people have had their tonsils removed or not, they still might develop tonsil cancer and should be educated about the disease. Answering questions about tonsil cancer is Ann Gillenwater, M. D., associate professor in M. D. Anderson's Department of Head and Neck Surgery and director of the cancer center's Oral Cancer Prevention Clinic. What are tonsils? The tonsils are a collection of lymph tissue, or white blood cells, at the back of your mouth that gather there to help fight infection. What raises the risk of tonsil cancer? Traditionally, the known risk factors for tonsil cancer are tobacco and alcohol use, but now there seems to be an increased rate of tonsil cancer in patients who don't smoke or drink. There is some evidence that it's related to the human papillomavirus (HPV). Can you have tonsil cancer and no tonsils? Even if you have had your tonsils removed (tonsillectomy), you can still get tonsil cancer because during the procedure, some tonsil tissue is left behind. What are the symptoms of tonsil cancer? The number one symptom is asymmetrical tonsils, having one tonsil larger than the other. Another symptom is a persistent sore throat. At later stages, there are enlarged lymph nodes or cysts in the neck and maybe ear pain. As a general rule, any time someone is thought to have a tonsil infection and antibiotics don't work, doctors should consider tonsil cancer. Many times tonsil cancer that has metastasized or spread to [...]

6/8/2008 Washington, D.C. Windsor Genova All Headline News (www.allheadlinenews.com) Using laser light to destroy cancer cells has been found to be safer in treating throat cancers than surgery, radiation and chemotherapy. Dr. H. Steven Sims, assistant professor of otolaryngology and director of University of Illinois-Chicago's Chicago Institute for Voice Care, used photodynamic therapy to completely removed the cancer from around the vocal folds of patient Sammie Bush without affecting his voice. The procedure was done on May 15. In photodynamic therapy, the patient is injected with a light-activate drug that makes all cells in the body very sensitive to light. After two days, normal cells will return to their original state but the cancerous cells will retain the drug. A laryngoscope is then used to beam laser light with a specific wavelength to the cancerous cells. A biochemical reaction disintegrates the cells in a few days. According to Sim, the laser technique saves the patient the inconvenience and cost of the repeated traditional medical procedures. It is also fast, does not require surgery, minimally invasive and cures oral and laryngeal cancers at a rate of 90 to 94 percent after one treatment. "Best of all, normal tissues around the malignancies are left undamaged," Sims said, according to Newswise.com. He added that photodynamic therapy allows patients to quickly use their voice. In contrast, a radiation procedure requires longer treatment and may cause voice to temporarily deteriorate. The only side effect of the laser technique is the skin's sensitivity to light for [...]

6/8/2008 Chicago, IL Jeremy Manier Chicago Tribute (www.chicagotribune.com) Dental exams are considered the first line of defense for many forms of oral cancer, but the usefulness of such screening is unclear for HPV-related throat cancer. Such tumors usually appear in the upper throat, which can be too far back for routine oral inspections to find them, experts said. "Often we'll get a referral from a dentist, but to be honest most of these patients' tumors are not detected that way," said Dr. Ezra Cohen, an oncologist at the University of Chicago Medical Center. One of the most common ways of catching such cancers is during a routine physical, when doctors feel the patient's neck for enlarged lymph nodes. If a patient or doctor feels a growth on the upper neck, the next step is often referral to an ear-nose-throat specialist, who can examine the upper throat by using an optical scope that's guided down through the nose. Although it's difficult for dentists to catch HPV-positive throat cancers, a thorough dental exam can catch oral cancer at an early stage. A study presented in April at the meeting of the American Academy of Dental Research suggests that patients with HPV and swollen gums are at increased risk of tongue cancer. Dr. Mine Tezal, a co-author of that paper, said dentists usually look for red or white discoloration of the gums, tongue or inside of the cheek. "Anybody can have red and white lesions, but they usually heal in a couple of [...]

6/6/2008 Dallas, TX Jessica Meyers Dallas Morning News (www.dallasnews.com) Katherine Kimzey started suffering debilitating headaches, fainting spells and arthritis-like stiffness last November. Six weeks later, the 14-year-old Dallas resident became so dizzy she could barely walk. She was hospitalized and missed three weeks of school. Then, she had a seizure. For weeks, she bounced back and forth between specialists and was eventually diagnosed with epilepsy. Katherine's mother, Michelle Kimzey, now believes her daughter's symptoms were caused by a new vaccine that was supposed to protect her against cervical cancer. The symptoms started not long after Katherine had her second shot late last year, she said. And they mirrored many of the 5,000 reports filed by the public through a national database that monitors the safety of vaccines after they are licensed. "When you read everybody's stories, they're too similar not to be related," Mrs. Kimzey said. But officials with the Centers for Disease Control and Prevention and doctors nationwide said such concerns about the drug are unfounded and most significant side effects reported are unrelated to the vaccine. "The safety of the vaccine is being very closely monitored," said John Iskander, acting director for immunization safety at the CDC, which runs the database along with the Food and Drug Administration. "There certainly have been high-profile suspected side effects, some reports of deaths," he said, "but those have been investigated and they don't appear to have been causally related." The recommendations have not changed and the vaccine will remain available, he [...]

6/3/2008 Chicago, IL press release EurekAlert.com Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of cetuximab to chemotherapy, according to a University of Pittsburgh Cancer Institute (UPCI) phase II study. The results will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago as an oral presentation. In the study, 39 patients with stages 3 or 4 head and neck cancer were treated initially with a combination of docetaxel, cisplatin and cetuximab, after which they received radiation therapy and additional cisplatin and cetuximab. Cetuximab, approved by the U.S. Food and Drug Administration in March 2006 and also known as Erbitux, is often prescribed for metastatic colorectal cancer and is used in conjunction with radiation therapy to treat squamous cell carcinomas of the head and neck. This is the first time it has been used in combination with docetaxel and cisplatin as induction therapy. “We found that adding cetuximab to standard chemotherapy helped head and neck cancer patients respond better to treatment. Out of 37 patients, 32 responded to induction treatment for an 86 percent response rate, and all patients had their tumors reduced, either partially or completely, after radiation was completed,” said Ethan Argiris, M.D., lead investigator and medical director of the aerodigestive cancers program and co-leader of the head and neck cancer program of UPCI. Further evaluation of this treatment shows that the complete disappearance of the primary tumor occurred in about 80 [...]

6/3/2008 New York, NY edited by Andre Grenon Reuters News (www.reuters.com) A promising vaccine to treat brain cancer developed by Avant Immunotherapeutics Inc may also hold promise against numerous other types of cancer, Interim Chief Executive Anthony Marucci said in an interview. Researchers said on Monday that Avant's vaccine, licensed by Pfizer Inc in April, more than doubled the survival time in patients with the most common and deadly type of brain tumor in a clinical trial. Marucci, whose company is guaranteed an undisclosed double- digit royalty on Pfizer's future sales of the product, said the world's largest drugmaker has the money and could have the desire to greatly widen the scope of research on the vaccine. "My guess is they would want to do larger studies in different indications, like head and neck cancer, ovarian and prostate cancer," Marucci said in a recent interview, noting that such studies could cost hundreds of millions of dollars. The vaccine works by targeting a receptor to a type of protein called epidermal growth factor that has a mutation only found in cancer cells. In the recently completed trial, the vaccine was used in combination with Temodar, a brain cancer drug sold by Schering- Plough Corp. "The only side effect you have with the vaccine is that it gives you a little redness around the site where it is injected, so the safety profile is an added bonus," Marucci said. "In oncology, any time you have a mild side effect profile, you're grateful." [...]

6/2/2008 Alexandria, VA staff Genetic Engineering and Biotechnology News (www.genengnews.com) A new study published in the June 2008 edition of Otolaryngology Head and Neck Surgery focus on what role gender plays in the prognosis of oral tongue cancer. This study is a prime examples of the wide variety of critical research being undertaken every day by otolaryngologist-head and neck surgeons; research that will improve physicians ability to provide the best patient care for the ear, nose, throat, head and neck, said journal editor Richard M. Rosenfeld, MD. Researchers at the University of Milano-Bicocca, Italy, found that although oral cancer is more prevalent in men, in their study group of 71 women and 142 men diagnosed with tongue cancer, gender did not influence prognosis. Based on this, the researchers concluded that employing a less aggressive course of treatment in female patients due to their gender was not justified.